
Name: | Dexamethasone Acetate EP Impurity C |
Catalogue No. | VL273019 |
CAS No. | N/A |
Molecular Formula | C24H31FO6 |
Molecular Weight | 434.5 |
Status | In-stock |
IUPAC Name | 9-fluoro-11β,17β-dihydroxy-16α-methyl-3,20-dioxopregna-1,4-dien-21-yl acetate |
Appearance | White Powder |
Description | Dexamethasone Acetate EP Impurity C or 9-fluoro-11β,17β-dihydroxy-16α-methyl-3,20-dioxopregna-1,4-dien-21-yl acetate is a debasement of Dexamethasone. Dexamethasone drug delivery system (DDS) was later developed as a biodegradable intravitreal implant to give a sustained delivery of 700 μg of dexamethasone to the retina and vitreous and is sanctioned by the FDA. |
References | Dongala, Thirupathi, et al. “Stability Indicating LC Method Development for Hydroxychloroquine Sulfate Impurities as Available for Treatment of COVID-19 and Evaluation of Risk Assessment prior to Method Validation by Quality by Design Approach.” Chromatographia, vol. 83, no. 10, Aug. 2020, pp. 1269–81,https://doi.org/10.1007/s10337-020-03945-5.London, Nikolas J. S., et al. “The Dexamethasone Drug Delivery System: Indications and Evidence.” Advances in Therapy, vol. 28, no. 5, Mar. 2011, pp. 351 |